The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...
Bristol Myers Squibb has expanded its direct-to-consumer (DTC) sales of medicines in the US with the addition of its psoriasis therapy Sotyktu. All of the DTC channels offer discounts for people ...
Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS ...
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...
The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results